Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study
Annals of Oncology, 06/15/2012
Clinical Article
Poprach A et al. – The presence of skin toxicity is associated with improved overall survival (OS) and progression–free survival (PFS) in patients with metastatic renal cell cancer (mRCC) treated with sunitinib.



